` 041830 (InBody Co Ltd) vs KOSPI 200 Comparison - Alpha Spread

I
041830
vs
K
KOSPI 200

Over the past 12 months, InBody Co Ltd has outperformed KOSPI 200, delivering a return of +68% compared to KOSPI 200's +50% growth.

Stocks Performance
041830 vs KOSPI 200

Loading...
041830
KOSPI 200
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
041830 vs KOSPI 200

Loading...
041830
KOSPI 200
Difference
www.alphaspread.com

Performance By Year
041830 vs KOSPI 200

Loading...
041830
KOSPI 200
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
InBody Co Ltd vs Peers

KOSPI 200
041830
ABT
ISRG
MDT
SYK
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

InBody Co Ltd
Glance View

Market Cap
627.5B KRW
Industry
Health Care

InBody makes body composition analysis devices that measure things like muscle, fat, and water using electrical impedance technology. It sells these machines to hospitals, clinics, research centers, gyms, schools, and wellness businesses that want a quick way to track a person’s physical condition beyond simple weight or BMI. The company earns money by selling the analyzers themselves and, in some cases, by selling related software, accessories, and service support. Its main customers are health care professionals, fitness operators, and institutions that use the devices for screening, treatment follow-up, training programs, and wellness assessments. What makes InBody’s business different is that it sits between medical equipment and fitness testing. Its devices turn body composition data into a routine measurement tool, which gives it a niche role in both clinical and nonclinical settings and makes its products useful to buyers who need repeatable, easy-to-use health data.

Intrinsic Value
₩34 843.45
Overvaluation 25%
Intrinsic Value
Price ₩46 550
I
Back to Top